Page 16 - Read Online

Page 12 Bozzetti et al. Neuroimmunol Neuroinflammation 2021;8:1-13 I http://dx.doi.org/10.20517/2347-8659.2020.26

41. Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol
2018;14:577-89.
42. Kuhle J, Disanto G, Lorscheider J, Stites T, Chen Y, et al. Fingolimod and CSF neurofilament light chain levels in relapsing remitting
multiple sclerosis. Neurology 2015;84:1639-43.
43. Kuhle J, Plattner K, Bestwick JP, Lindberg RL, Ramagopalan SV, et al. A comparative study of CSF neurofilament light and heavy chain
protein in MS. Mult Scler 2013;19:1597-603.
44. Kuhle J, Malmeström C, Axelsson M, Plattner K, Yaldizli Ö, et al. Neurofilament light and heavy subunits compared as therapeutic
biomarkers in multiple sclerosis. Acta Neurol Scand 2013;128:e33-6.
45. Kuhle J, Barro C, Disanto G, Mathias A, Soneson C, et al. Serum neurofilament light chain in early relapsing remitting MS is increased
and correlates with CSF levels and with MRI measures of disease severity. Mult Scler 2016;22:1550-9.
46. Sejbaek T, Nielsen HH, Penner N, Plavina T, Mendoza JP, et al. Dimethyl fumarate decreases neurofilament light chain in CSF and blood
of treatment naïve relapsing MS patients. J Neurol Neurosurg Psychiatry 2019;90:1324-30.
47. Kuhle J, Plavina T, Barro C, Disanto G, Sangurdekar D, et al. Neurofilament light levels are associated with long-term outcomes in
multiple sclerosis. Mult Scler 2019;1352458519885613.
48. Håkansson I, Tisell A, Cassel P, Blennow K, Zetterberg H, et al. Neurofilament levels, disease activity and brain volume during follow-up
in multiple sclerosis. J Neuroinflammation 2018;15:209.
49. Novakova L, Zetterberg H, Sundström P, Axelsson M, Khademi M, et al. Monitoring disease activity in multiple sclerosis using serum
neurofilament light protein. Neurology 2017;89:2230-7.
50. Burman J, Zetterberg H, Fransson M, Loskog AS, Raininko R, et al. Assessing tissue damage in multiple sclerosis: a biomarker approach.
Acta Neurol Scand 2014;130:81-9.
51. Barro C, Benkert P, Disanto G, Tsagkas C, Amann M, et al. Serum neurofilament as a predictor of disease worsening and brain and spinal
cord atrophy in multiple sclerosis. Brain 2018;141:2382-91.
52. Siller N, Kuhle J, Muthuraman M, Barro C, Uphaus T, et al. Serum neurofilament light chain is a biomarker of acute and chronic neuronal
damage in early multiple sclerosis. Mult Scler 2019;25:678-86.
53. de Flon P, Gunnarsson M, Laurell K, Söderström L, Birgander R, et al. Reduced inflammation in relapsing-remitting multiple sclerosis
after therapy switch to rituximab. Neurology 2016;87:141-7.
54. Bhan A, Jacobsen C, Myhr KM, Dalen I, Lode K, et al. Neurofilaments and 10-year follow-up in multiple sclerosis. Mult Scler
2018;24:1301-7.
55. Giovannoni G, Turner B, Gnanapavan S, Offiah C, Schmierer K, et al. Is it time to target no evident disease activity (NEDA) in multiple
sclerosis? Mult Scler Relat Disord 2015;4:329-33.
56. Giovannoni G, Tomic D, Bright JR, Havrdová E. “No evident disease activity”: The use of combined assessments in the management of
patients with multiple sclerosis. Mult Scler 2017;23:1179-87.
57. Delcoigne B, Manouchehrinia A, Barro C, Benkert P, Michalak Z, et al. Blood neurofilament light levels segregate treatment effects in
multiple sclerosis. Neurology 2020;94:e1201-12.
58. Salzer J, Svenningsson A, Sundström P. Neurofilament light as a prognostic marker in multiple sclerosis. Mult Scler 2010;16:287-92.
59. Norgren N, Sundström P, Svenningsson A, Rosengren L, Stigbrand T, et al. Neurofilament and glial fibrillary acidic protein in multiple
sclerosis. Neurology 2004;63:1586-90.
60. Trentini A, Comabella M, Tintoré M, Koel-Simmelink MJ, Killestein J, et al. N-acetylaspartate and neurofilaments as biomarkers of
axonal damage in patients with progressive forms of multiple sclerosis. J Neurol 2014;261:2338-43.
61. Damasceno A, Dias-Carneiro RPC, Moraes AS, Boldrini VO, Quintiliano RPS, et al. Clinical and MRI correlates of CSF neurofilament
light chain levels in relapsing and progressive MS. Mult Scler Relat Disord 2019;30:149-53.
62. Sellebjerg F, Börnsen L, Ammitzbøll C, Nielsen JE, Vinther-Jensen T, et al. Defining active progressive multiple sclerosis. Mult Scler
2017;23:1727-35.
63. Martin SJ, McGlasson S, Hunt D, Overell J. Cerebrospinal fluid neurofilament light chain in multiple sclerosis and its subtypes: a meta-
analysis of case-control studies. J Neurol Neurosurg Psychiatry 2019;90:1059-67.
64. Romme Christensen J, Komori M, von Essen MR, Ratzer R, Börnsen L, et al. CSF inflammatory biomarkers responsive to treatment in
progressive multiple sclerosis capture residual inflammation associated with axonal damage. Mult Scler 2019;25:937-46.
65. Ferraro D, Guicciardi C, De Biasi S, Pinti M, Bedin R, et al. Plasma neurofilaments correlate with disability in progressive multiple
sclerosis patients. Acta Neurol Scand 2020;141:16-21.
66. Williams T, Zetterberg H, Chataway J. Neurofilaments in progressive multiple sclerosis: a systematic review. J Neurol 2020; doi: 10.1007/
s00415-020-09917-x.
67. Sato DK, Lana-Peixoto MA, Fujihara K, de Seze J. Clinical spectrum and treatment of neuromyelitis optica spectrum disorders: evolution
and current status. Brain Pathol 2013;23:647-60.
68. Flanagan EP. Neuromyelitis optica spectrum disorder and other non-multiple sclerosis central nervous system inflammatory diseases.
Continuum (Minneap Minn) 2019;25:815-44.
69. Huh SY, Kim SH, Hyun JW, Jeong IH, Park MS, et al. Short segment myelitis as a first manifestation of neuromyelitis optica spectrum
disorders. Mult Scler 2017;23:413-9.
70. Wingerchuk DM, Hogancamp WF, O’Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic’s syndrome).
Neurology 1999;53:1107-14.
71. Palace J, Lin DY, Zeng D, Majed M, Elsone L, et al. Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum